Myovant Sciences Ltd Stock News

Shares of Myovant Sciences Ltd. MYOV, +2.34% shot up 27.2% in premarket trading Monday toward an 11-month high, after the biopharmaceutical company confirmed over the weekend that it received an unsol

The compelling results of endometriosis treatment MYFEMBREE's phase 3 led to the drug's approval, and Myovant will be eligible for up to $200 million based on achieving certain milestones. The endomet

BASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, e

Myovant secured FDA approval for Myfembree for the treatment of endometriosis in early August. The approval clears the regulatory overhang on the stock but now comes the harder part - commercializatio

Myovant Sciences Ltd. (NYSE:MYOV ) Q1 2022 Results Conference Call July 27, 2022 5:00 PM ET Company Participants Uneek Mehra - Chief Financial & Business Officer Dave Marek - Chief Executive Officer L

Myovant has performed well since the regulatory setback in April. The PDUFA date for the sNDA for Myfembree has been extended by three months and Orgovyx was approved in Europe.

BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for

Myovant Sciences (MYOV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more st

BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies

BASEL, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,

BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,

BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, em

BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accep

MYOV earnings call for the period ending March 31, 2022.

Myovant Sciences Ltd. (NYSE:MYOV ) Q4 2021 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Uneek Mehra - Chief Financial & Business Officer Dave Marek - Chief Executive Officer L